Literature DB >> 21221959

Interaction of oxycodone and voriconazole-a case series of patients with cancer pain supports the findings of randomised controlled studies with healthy subjects.

Nora M Hagelberg, Tuija H Nieminen, Teijo I Saari, Mikko Neuvonen, Pertti J Neuvonen, Kari Laine, Klaus T Olkkola.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21221959     DOI： 10.1007/s00228-010-0969-0

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  9 in total

1.  Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.

Authors:  Juha Grönlund; Teijo I Saari; Nora M Hagelberg; Pertti J Neuvonen; Klaus T Olkkola; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

2.  Effects of voriconazole co-administration on oxycodone-induced adverse events: a case in the retrospective survey.

Authors:  Masaaki Watanabe; Masato Homma; Kenji Momo; Yasushi Okoshi; Tetsuro Wada; Akira Hara; Shigeru Chiba; Yukinao Kohda
Journal:  Eur J Clin Pharmacol       Date:  2011-01-08       Impact factor: 2.953

3.  Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.

Authors:  C F Samer; Y Daali; M Wagner; G Hopfgartner; C B Eap; M C Rebsamen; M F Rossier; D Hochstrasser; P Dayer; J A Desmeules
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

4.  The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.

Authors:  C F Samer; Y Daali; M Wagner; G Hopfgartner; C B Eap; M C Rebsamen; M F Rossier; D Hochstrasser; P Dayer; J A Desmeules
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

5.  Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.

Authors:  Oliver Kummer; Felix Hammann; Claudine Moser; Olivier Schaller; Jürgen Drewe; Stephan Krähenbühl
Journal:  Eur J Clin Pharmacol       Date:  2010-09-21       Impact factor: 2.953

6.  Grapefruit juice enhances the exposure to oral oxycodone.

Authors:  Tuija H Nieminen; Nora M Hagelberg; Teijo I Saari; Mikko Neuvonen; Pertti J Neuvonen; Kari Laine; Klaus T Olkkola
Journal:  Basic Clin Pharmacol Toxicol       Date:  2010-10       Impact factor: 4.080

7.  Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir.

Authors:  Tuija H Nieminen; Nora M Hagelberg; Teijo I Saari; Mikko Neuvonen; Pertti J Neuvonen; Kari Laine; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2010-08-10       Impact factor: 2.953

8.  Voriconazole drastically increases exposure to oral oxycodone.

Authors:  Nora M Hagelberg; Tuija H Nieminen; Teijo I Saari; Mikko Neuvonen; Pertti J Neuvonen; Kari Laine; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2008-10-03       Impact factor: 2.953

9.  Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone.

Authors:  Teijo I Saari; Juha Grönlund; Nora M Hagelberg; Mikko Neuvonen; Kari Laine; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2010-04       Impact factor: 2.953
  9 in total
  2 in total

Review 1.  Clinically significant drug-drug interactions involving opioid analgesics used for pain treatment in patients with cancer: a systematic review.

Authors:  Aleksandra Kotlinska-Lemieszek; Pål Klepstad; Dagny Faksvåg Haugen
Journal:  Drug Des Devel Ther       Date:  2015-09-16       Impact factor: 4.162

2.  Pharmacogenomic considerations in opioid analgesia.

Authors:  Pascal H Vuilleumier; Ulrike M Stamer; Ruth Landau
Journal:  Pharmgenomics Pers Med       Date:  2012-08-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.